Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process.

about

Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process.

Item

http://www.wikidata.org/entity/Q54565907

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Preclinical assessment of nove ...... in the drug discovery process.

@en

Preclinical assessment of nove ...... in the drug discovery process.

@nl

type

Item

label

Preclinical assessment of nove ...... in the drug discovery process.

@en

Preclinical assessment of nove ...... in the drug discovery process.

@nl

prefLabel

Preclinical assessment of nove ...... in the drug discovery process.

@en

Preclinical assessment of nove ...... in the drug discovery process.

@nl

P1476

Preclinical assessment of nove ...... in the drug discovery process.

@en

P2093

Bruno Alicke

http://www.w3.org/2001/XMLSchema#string

Edna F Choo

http://www.w3.org/2001/XMLSchema#string

Jason Boggs

http://www.w3.org/2001/XMLSchema#string

Joachim Rudolph

http://www.w3.org/2001/XMLSchema#string

Jonas Grina

http://www.w3.org/2001/XMLSchema#string

Kapil Menghrajani

http://www.w3.org/2001/XMLSchema#string

Kristina West

http://www.w3.org/2001/XMLSchema#string

Steve Wenglowsky

http://www.w3.org/2001/XMLSchema#string

Vikki Dinkel

http://www.w3.org/2001/XMLSchema#string

Yingqing Ran

http://www.w3.org/2001/XMLSchema#string

P2860

Back to the roots: the remarkable RAF oncogene story

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Ultrasensitivity in the mitogen-activated protein kinase cascade

Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline

Pyrazolopyridine Inhibitors of B-Raf V600E . Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors

Mutations of the BRAF gene in human cancer

Hyperactive Ras in developmental disorders and cancer

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations.

Diversity of mechanism-based pharmacodynamic models.

P304

1076-1087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/00498254.2011.603384

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stephen E. Gould

P577

2011-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21864203

http://www.w3.org/2001/XMLSchema#string